MedTrace Logo

Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

NCT03341429 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-11-05

No results posted yet for this study

Summary

A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery

Conditions

Interventions

DRUG

Liraglutide Pen Injector [Saxenda]

Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.

DRUG

Placebo

Daily subcutaneous injection

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Rachel L Batterham, PhD FRCP · UCL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-22
Primary Completion
2019-11-28
Completion
2020-06-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03341429 on ClinicalTrials.gov